{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:39:33Z","timestamp":1761863973028,"version":"3.37.3"},"reference-count":18,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670150"],"award-info":[{"award-number":["81670150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0529-9","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T12:02:40Z","timestamp":1550750560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Tongjuan","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9790-859X","authenticated-orcid":false,"given":"Xiaoxi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"issue":"10","key":"529_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, et al. Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis. Leuk Res. 2013;37(10):1271\u20137.","journal-title":"Leuk Res"},{"issue":"8","key":"529_CR2","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, et al. Phase I first-in-human study of Venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol. 2017;35(8):826\u201333.","journal-title":"J Clin Oncol"},{"issue":"13","key":"529_CR3","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","volume":"378","author":"CS Tam","year":"2018","unstructured":"Tam CS, et al. Ibrutinib plus Venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211\u201323.","journal-title":"N Engl J Med"},{"issue":"1","key":"529_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ymthe.2016.10.020","volume":"25","author":"FL Locke","year":"2017","unstructured":"Locke FL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25(1):285\u201395.","journal-title":"Mol Ther"},{"issue":"12","key":"529_CR5","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1182\/blood-2011-10-384388","volume":"119","author":"JN Kochenderfer","year":"2012","unstructured":"Kochenderfer JN, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119(12):2709\u201320.","journal-title":"Blood"},{"issue":"16","key":"529_CR6","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","volume":"35","author":"JN Kochenderfer","year":"2017","unstructured":"Kochenderfer JN, et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum Interleukin-15 levels. J Clin Oncol. 2017;35(16):1803\u201313.","journal-title":"J Clin Oncol"},{"issue":"8","key":"529_CR7","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1089\/hum.2015.054","volume":"26","author":"G Enblad","year":"2015","unstructured":"Enblad G, Karlsson H, Loskog ASI. CAR T-cell therapy: the role of physical barriers and immunosuppression in lymphoma. Hum Gene Ther. 2015;26(8):498\u2013505.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"529_CR8","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/cgt.2013.35","volume":"20","author":"H Karlsson","year":"2013","unstructured":"Karlsson H, et al. Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy. Cancer Gene Ther. 2013;20(7):386\u201393.","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"529_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/MOH.0000000000000181","volume":"22","author":"Y Yang","year":"2015","unstructured":"Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015;22(6):509\u201315.","journal-title":"Curr Opin Hematol"},{"issue":"5","key":"529_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563\u201371.","journal-title":"Nat Med"},{"issue":"18","key":"529_CR11","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1182\/blood-2017-12-815548","volume":"132","author":"H Qin","year":"2018","unstructured":"Qin H, et al. Murine pre\u2013B-cell ALL induces T-cell dysfunction not fully reversed by introduction of a chimeric antigen receptor. Blood. 2018;132(18):1899\u2013910.","journal-title":"Blood"},{"issue":"6","key":"529_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1158\/2326-6066.CIR-15-0276","volume":"4","author":"GA Rufener","year":"2016","unstructured":"Rufener GA, et al. Preserved activity of CD20-specific chimeric antigen receptor-expressing T cells in the presence of rituximab. Cancer Immunol Res. 2016;4(6):509\u201319.","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"529_CR13","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-15-1527","volume":"22","author":"M Ruella","year":"2016","unstructured":"Ruella M, et al. The addition of the BTK inhibitor Ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684\u201396.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"529_CR14","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1182\/blood-2015-11-679134","volume":"127","author":"JA Fraietta","year":"2016","unstructured":"Fraietta JA, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117\u201327.","journal-title":"Blood"},{"issue":"25","key":"529_CR15","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2016-01-688796","volume":"127","author":"MA Anderson","year":"2016","unstructured":"Anderson MA, et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood. 2016;127(25):3215\u201324.","journal-title":"Blood"},{"issue":"16","key":"529_CR16","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez F, et al. Pharmacological and protein profiling suggests Venetoclax (ABT-199) as optimal partner with Ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2015;21(16):3705\u201315.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"529_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u20138.","journal-title":"Nat Immunol"},{"issue":"12","key":"529_CR18","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1182\/blood-2008-03-077974","volume":"112","author":"HJ Kolb","year":"2008","unstructured":"Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112(12):4371\u201383.","journal-title":"Blood"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:46:52Z","timestamp":1601056012000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0529-9","relation":{},"ISSN":["2051-1426"],"issn-type":[{"type":"electronic","value":"2051-1426"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"20 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical ethics committee of Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology (TJ-IRB20160310). The patient and donor gave their written informed consent in accordance with the Declaration of Helsinki. This study is registered at  as ChiCTR-OPN-16008526, ChiCTR1800019385 and ChiCTR1800019449.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have obtained consent to publish from the participant to report individual patient data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"51"}}